Cargando…
Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models
INTRODUCTION: Prostate cancer is one of the most commonly diagnosed malignancies in men with high mortality rates. Despite the recent therapeutic advances, such as immunotherapies, survival of patients with advance disease remains significantly low. Blockade of immune checkpoints has led to low resp...
Autores principales: | Papaevangelou, Efthymia, Esteves, Ana M., Dasgupta, Prokar, Galustian, Christine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350564/ https://www.ncbi.nlm.nih.gov/pubmed/37465665 http://dx.doi.org/10.3389/fimmu.2023.1196829 |
Ejemplares similares
-
Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer
por: Esteves, Ana M., et al.
Publicado: (2021) -
Cytotopic (Cyto-) IL-15 as a New Immunotherapy for Prostate Cancer: Recombinant Production in Escherichia coli and Purification
por: Esteves, Ana M., et al.
Publicado: (2021) -
Liposomal Delivery of MIW815 (ADU-S100) for Potentiated STING Activation
por: Ji, Nan, et al.
Publicado: (2023) -
Targeting Prostate Cancer Using Intratumoral Cytotopically Modified Interleukin-15 Immunotherapy in a Syngeneic Murine Model
por: Papaevangelou, Efthymia, et al.
Publicado: (2020) -
IL-15 Upregulates Telomerase Expression and Potently Increases Proliferative Capacity of NK, NKT-Like, and CD8 T Cells
por: Watkinson, Fiona, et al.
Publicado: (2021)